ARTICLE | Company News
ImmunoGen news
January 3, 1995 8:00 AM UTC
IMGN is cutting its work force to 80 employees from 180, cutting executive salaries by 20 percent and will focus its resources on Oncolysin B, its lead product in Phase III trials to prevent relapses in lymphoma patients.
Until it secures further funding, the Cambridge, Mass., company is suspending work on its other Oncolysin products and its small-drug immunoconjugates. ...